First-line axitinib versus sorafenib in Asian patients with metastatic renal cell carcinoma: exploratory subgroup analyses of Phase III data
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
First-line axitinib versus sorafenib in Asian patients with metastatic renal cell carcinoma: exploratory subgroup analyses of Phase III data
Authors
Keywords
-
Journal
Future Oncology
Volume -, Issue -, Pages -
Publisher
Future Medicine Ltd
Online
2018-07-30
DOI
10.2217/fon-2018-0442
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Overall survival in renal cell carcinoma after introduction of targeted therapies: a Norwegian population-based study
- (2017) Christian Beisland et al. OncoTargets and Therapy
- Comparison of PFS and safety for Asian compared to North American and European populations in the phase III trial of pazopanib versus sunitinib in patients with treatment-naive RCC (COMPARZ).
- (2017) Jun Guo et al. JOURNAL OF CLINICAL ONCOLOGY
- Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†
- (2016) B. Escudier et al. ANNALS OF ONCOLOGY
- Cancer incidence and mortality projections in the UK until 2035
- (2016) C R Smittenaar et al. BRITISH JOURNAL OF CANCER
- Overall Survival Analysis From a Randomized Phase II Study of Axitinib With or Without Dose Titration in First-Line Metastatic Renal Cell Carcinoma
- (2016) Brian I. Rini et al. Clinical Genitourinary Cancer
- Key predictive factors for efficacy of axitinib in first-line metastatic renal cell carcinoma: subgroup analysis in Japanese patients from a randomized, double-blind phase II study
- (2016) Yoshihiko Tomita et al. JAPANESE JOURNAL OF CLINICAL ONCOLOGY
- Cancer Characteristics and Current Treatments of Patients with Renal Cell Carcinoma in Sweden
- (2015) Andreas Thorstenson et al. Biomed Research International
- Survival among patients with advanced renal cell carcinoma in the pretargeted versus targeted therapy eras
- (2015) Pengxiang Li et al. Cancer Medicine
- Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
- (2014) Jacques Ferlay et al. INTERNATIONAL JOURNAL OF CANCER
- Critical appraisal of sorafenib in the treatment of Chinese patients with renal cell carcinoma
- (2014) Ding-Wei Ye et al. OncoTargets and Therapy
- Treatment and overall survival in renal cell carcinoma: a Swedish population-based study (2000–2008)
- (2013) T Wahlgren et al. BRITISH JOURNAL OF CANCER
- The Effect of Targeted Therapy on Overall Survival in Advanced Renal Cancer: A Study of the National Surveillance Epidemiology and End Results Registry Database
- (2013) Ulka Vaishampayan et al. Clinical Genitourinary Cancer
- Improved overall survival after implementation of targeted therapy for patients with metastatic renal cell carcinoma: Results from the Danish Renal Cancer Group (DARENCA) study-2
- (2013) Anne V. Soerensen et al. EUROPEAN JOURNAL OF CANCER
- Tivozanib Versus Sorafenib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma: Results From a Phase III Trial
- (2013) Robert J. Motzer et al. JOURNAL OF CLINICAL ONCOLOGY
- Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial
- (2013) Thomas E Hutson et al. LANCET ONCOLOGY
- Axitinib with or without dose titration for first-line metastatic renal-cell carcinoma: a randomised double-blind phase 2 trial
- (2013) Brian I Rini et al. LANCET ONCOLOGY
- Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma
- (2013) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Skin toxicity and efficacy of sunitinib and sorafenib in metastatic renal cell carcinoma: a national registry-based study
- (2012) A. Poprach et al. ANNALS OF ONCOLOGY
- Cytochrome P450 variations in different ethnic populations
- (2012) Joseph McGraw et al. Expert Opinion on Drug Metabolism & Toxicology
- Population Differences in Major Functional Polymorphisms of Pharmacokinetics/pharmacodynamics-related Genes in Eastern Asians and Europeans: Implications in the Clinical Trials for Novel Drug Development
- (2011) Kouichi Kurose et al. Drug Metabolism and Pharmacokinetics
- Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial
- (2011) Brian I Rini et al. LANCET
- ABCG2 421C>A polymorphism and high exposure of sunitinib in a patient with renal cell carcinoma
- (2010) T. Mizuno et al. ANNALS OF ONCOLOGY
- The Efficacy and Safety of Sunitinib in Korean Patients with Advanced Renal Cell Carcinoma: High Incidence of Toxicity Leads to Frequent Dose Reduction
- (2010) C. Yoo et al. JAPANESE JOURNAL OF CLINICAL ONCOLOGY
- Efficacy of sorafenib on metastatic renal cell carcinoma in Asian patients: Results from a multicenter study
- (2009) Hailiang Zhang et al. BMC CANCER
- Treatment Outcomes of Sunitinib Treatment in Advanced Renal Cell Carcinoma Patients: A Single Cancer Center Experience in Korea
- (2009) Min Hee Hong et al. Cancer Research and Treatment
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now